22 results on '"Martin-Doyle, W."'
Search Results
2. Emerging Strategies in Adjuvant Immunotherapy: A Comparative Review of Bladder Cancer and Renal Cell Carcinoma Treatments.
- Author
-
Balli, Sevinc, Bolek, Hatice, and Ürün, Yüksel
- Abstract
Recent progress in adjuvant immunotherapy offers hope for improving disease-free survival in high-risk bladder cancer (BC) and renal cell carcinoma (RCC). This review focuses on key trials such as CheckMate 274 and KEYNOTE-564, which show promising results with nivolumab in BC and pembrolizumab in RCC, including a 30% reduction in progression risk. Pembrolizumab also demonstrated overall survival (OS) benefit in RCC. The review also explores the potential of circulating tumor DNA (ctDNA) as a biomarker for better therapy selection and patient stratification. It emphasizes the need for ongoing research to establish survival benefits and suggests integrating biomarkers and risk stratification to optimize adjuvant immunotherapy in BC and RCC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Beyond Chemotherapy: Present and Future Perspectives in the Treatment of Lymphoproliferative Disorders.
- Author
-
Massaro, Fulvio, Andreozzi, Fabio, Abrassart, Tom, Castiaux, Julie, Massa, Hanne, Rizzo, Ornella, and Vercruyssen, Marie
- Subjects
LYMPHOPROLIFERATIVE disorders ,BISPECIFIC antibodies ,HODGKIN'S disease ,CHIMERIC antigen receptors ,HEMATOLOGIC malignancies - Abstract
Over the past three decades, the treatment of lymphoproliferative disorders has undergone profound changes, notably due to the increasing availability of innovative therapies with the potential to redefine clinical management paradigms. A major impact is related to the development of monoclonal antibodies, checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor T (CAR-T) cell therapies. This review discusses the current landscape of clinical trials targeting various hematological malignancies, highlighting promising early-phase results and strategies to overcome resistance. Lymphoproliferative disorders encompass a range of conditions: while in Hodgkin lymphoma (HL) the goal is to reduce chemotherapy-related toxicity by integrating immunotherapy into the frontline setting, peripheral T cell lymphoma (PTCL) lacks effective targeted therapies. The review emphasizes a shifting therapeutic landscape towards precision medicine and treatment modalities that are less toxic yet more effective. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Predictive and Prognostic Biomarkers and Tumor Antigens for Targeted Therapy in Urothelial Carcinoma.
- Author
-
Eturi, Aditya, Bhasin, Amman, Zarrabi, Kevin K., and Tester, William J.
- Subjects
TUMOR antigens ,PROGNOSIS ,TUMOR markers ,POLY ADP ribose ,EPIDERMAL growth factor receptors ,TRANSITIONAL cell carcinoma ,ADP-ribosylation ,FIBROBLAST growth factor receptors - Abstract
Urothelial carcinoma (UC) is the fourth most prevalent cancer amongst males worldwide. While patients with non-muscle-invasive disease have a favorable prognosis, 25% of UC patients present with locally advanced disease which is associated with a 10–15% 5-year survival rate and poor overall prognosis. Muscle-invasive bladder cancer (MIBC) is associated with about 50% 5 year survival when treated by radical cystectomy or trimodality therapy; stage IV disease is associated with 10–15% 5 year survival. Current therapeutic modalities for MIBC include neoadjuvant chemotherapy, surgery and/or chemoradiation, although patients with relapsed or refractory disease have a poor prognosis. However, the rapid success of immuno-oncology in various hematologic and solid malignancies offers new targets with tremendous therapeutic potential in UC. Historically, there were no predictive biomarkers to guide the clinical management and treatment of UC, and biomarker development was an unmet need. However, recent and ongoing clinical trials have identified several promising tumor biomarkers that have the potential to serve as predictive or prognostic tools in UC. This review provides a comprehensive summary of emerging biomarkers and molecular tumor targets including programmed death ligand 1 (PD-L1), epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), fibroblast growth factor receptor (FGFR), DNA damage response and repair (DDR) mutations, poly (ADP-ribose) polymerase (PARP) expression and circulating tumor DNA (ctDNA), as well as their clinical utility in UC. We also evaluate recent advancements in precision oncology in UC, while illustrating limiting factors and challenges related to the clinical application of these biomarkers in clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Recurrence After Atrial Fibrillation Ablation and Investigational Biomarkers of Cardiac Remodeling.
- Author
-
El-Harasis, Majd A., Quintana, Joseph A., Martinez-Parachini, J. Roberto, Jackson, Gregory G., Varghese, Bibin T., Yoneda, Zachary T., Murphy, Brittany S., Crawford, Diane M., Tomasek, Kelsey, Yan Ru Su, Wells, Quinn S., Roden, Dan M., Michaud, Gregory F., Saavedra, Pablo, Estrada, Juan Carlos, Richardson, Travis D., Kanagasundram, Arvindh N., Shen, Sharon T., Montgomery, Jay A., and Ellis, Christopher R.
- Published
- 2024
- Full Text
- View/download PDF
6. A systematic review and meta-analysis of intraarterial chemotherapy for non muscle invasive bladder cancer: Promising alternative therapy in high tuberculosis burden countries.
- Author
-
Rahman, Zakaria Aulia, Hidayatullah, Furqan, Lim, Jasmine, and Hakim, Lukman
- Subjects
BLADDER cancer ,ALTERNATIVE treatment for cancer ,NON-muscle invasive bladder cancer ,CANCER invasiveness ,TUBERCULOSIS ,BCG immunotherapy - Abstract
Introduction: Local therapies for high risk non-muscle-invasive bladder cancer (NMIBC) such as intravesical chemotherapy (IVC) have shown a high rate of progression and recurrence (1). Intravesical Bacillus Calmette-Guérin (BCG) for local therapies has been shown to reduce progression and recurrence in patient with NMIBC. However, its potential role is limited in high burden countries for tuberculosis (TB) due to its low specificity that can cause wrong diagnosis or false positive in patients with clinically diagnosed tuberculosis. BCG vaccine that has to be given for most people in tuberculosis endemic countries will induce trained immunity that could reduce the effectivity of intravesical BCG for NMIBC Moreover, intravesical BCG is contraindicated in patient with or previous tuberculosis. The potential clinical benefit of intraarterial chemotherapy (IAC) in delaying the recurrence and progression of high-risk NMIBC have been investigated with promising results (2, 3). We aimed to conduct a meta-analysis to evaluate the potential anti-tumor effect of IAC in NMIBC. Methods: We conducted a comprehensive search of published articles in Cochrane Library, Pubmed, and Science-Direct to identify relevant randomized controlled trials (RCTs) and observational studies comparing IAC alone or combined with IVC versus IVC/BCG alone in NMIBC. The protocol of preferred reporting items for systematic review and meta-analysis (PRISMA) was applied to this study. Results: Four RCTs and 4 cohort observational studies were eligible in this study and 5 studies were included in meta-analysis. The risk ratio of tumor recurrence was reduced by 35% (RR = 0.65; 95% CI 0.49-0.87; p = 0.004) in IAC plus IVC, while recurrence-free survival (RFS) was prolonged by 45% (HR: 0.55; 95% CI, 0.44-0.69; p < 0.001). The risk of tumor progression was reduced by 45% (RR = 0.55; 95% CI 0.41-0.75; p = 0.002) and tumor progression-free survival (PFS) was also prolonged by 53% (HR: 0.47; 95% CI, 0.34-0.65; p < 0.001). Some RCT's had high or unclear risk of bias, meanwhile 4 included cohort studies had overall low risk of bias, therefore the pooled results need to be interpreted cautiously. Subgroup analysis revealed that the heterogeneity outcome of tumour recurrence might be attributed to the difference in NMIBC stages and grades. Conclusions: The IAC alone or combined with IVC following bladder tumor resection may lower the risk of tumor recurrence and progression. These findings highlight the importance of further multi institutional randomized controlled trials with bigger sample size using a standardized IAC protocol to validate the current results. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Prognostic Values of Inflammatory Markers in Patients with High-grade Lamina Propria-invasive Bladder Cancer.
- Author
-
Yılmaz, İsmail Önder, Değer, Mutlu, Akdoğan, Nebil, Arıdoğan, İbrahim Atilla, Bayazıt, Yıldırım, and İzol, Volkan
- Subjects
MONOCYTE lymphocyte ratio ,PLATELET lymphocyte ratio ,NEUTROPHIL lymphocyte ratio ,PROGNOSIS ,NON-muscle invasive bladder cancer - Abstract
Objective: In this study, we investigated the prognostic values of various pathological and inflammatory parameters in patients with high-grade lamina propriainvasive (T1G3) bladder cancer (BC). Materials and Methods: Between 2006 and 2018, patients with pathological evaluation of T1G3 bladder urothelial carcinoma in our institution who did not meet the exclusion criteria were included in the study. Parameters such as gender, tumor diameter, tumor number, lamina propria invasion depth, presence of carcinoma in situ, presence of lymphovascular invasion (LVI), presence of variant histology, lymphocyte monocyte ratio (LMR), platelet lymphocyte ratio (PLR), neutrophil lymphocyte ratio (NLR), and systemic inflammatory markers (SIM) were statistically analyzed. Results: After the exclusion criteria were evaluated, 76 patients were included in the study from 157 patients. Recurrence was observed in 37 (48.68%) patients, and progression was observed in 21 (27.63%) patients. A significant relationship was discovered between LMR (p<0,001), PLR (p<0.004), NLR (p<0.002), tumor diameter (p<0.002), number of tumors (p<0,007), and SIM score (p<0,001) with the probability of recurrence. The probability of progression was associated with NLR (p<0.023), LVI (p<0.005), tumor diameter (p<0.012) and tumor number (p<0.001). A significant relationship was found between SIM (p<0.041) and recurrence-free survival. We found a significant relationship between LVI (p<0.022) and progression-free survival. Conclusions: In this study, we found positive correlations between some inflammatory markers and recurrence/progression in patients with T1G3 BC. According to our study, inflammatory parameters such as NLR, PLR, LMR, and SIM score should be evaluated while investigating the possibility of recurrence/progression in patients with T1G3 BC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. New risk stratification for adjuvant nivolumab for high‐risk muscle‐invasive urothelial carcinoma.
- Author
-
Saito, Takafumi, Kanao, Kent, Matsumoto, Kazuhiro, Fukumoto, Keishiro, Igarashi, Daisuke, Takahashi, Takayuki, Kaneko, Go, Shirotake, Suguru, Nishimoto, Koshiro, Mizuno, Ryuichi, Ishida, Masaru, Hara, Satoshi, Oya, Mototsugu, and Oyama, Masafumi
- Published
- 2024
- Full Text
- View/download PDF
9. Sexual dimorphism in bladder cancer: a review of etiology, biology, diagnosis, and outcomes.
- Author
-
Sheng Zhu and Huasheng Zhao
- Subjects
BLADDER cancer ,ETIOLOGY of cancer ,BIOLOGY ,DIAGNOSIS ,SEX hormones - Abstract
Bladder carcinoma represents a prevalent malignancy, wherein the influence of sex extends across its incidence, biological attributes, and clinical outcomes. This scholarly exposition meticulously examines pertinent investigations, elucidating the nuanced impact of sex on bladder cancer, and posits cogent avenues for future research and intervention modalities. In the initial discourse, an exhaustive scrutiny is undertaken of the etiological underpinnings of bladder cancer, encompassing variables such as tobacco consumption, occupational exposures, and genetic aberrations. Subsequently, a comprehensive dissection unfolds, delving into the intricate biological disparities inherent in sex vis-à-vis the initiation and progression of bladder cancer. This analytical framework embraces multifaceted considerations, spanning sex hormones, sex chromosomal dynamics, metabolic enzymatic cascades, and the intricate interplay with the microbiome. Lastly, a synthesized exposition encapsulates the ramifications of gender differentials on the diagnostic and prognostic landscapes of bladder cancer, underscoring the imperative for intensified investigative endeavors directed towards elucidating gender-specific variances and the formulation of tailored therapeutic strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer: Working Group 3: Subcategorization of T1 Bladder Cancer.
- Author
-
Lopez-Beltran, Antonio, Raspollini, Maria R., Hansel, Donna, Compérat, Eva, Williamson, Sean R., Liedberg, Fredrik, Iczkowski, Kenneth A., Bubendorf, Lukas, van der Kwast, Theodorus H., and Liang Cheng
- Published
- 2024
- Full Text
- View/download PDF
11. COL6A1 expression as a potential prognostic biomarker for risk stratification of T1 high grade bladder cancer: Unveiling the aggressive nature of a distinct non-muscle invasive subtype.
- Author
-
Kyeong Kim, Young Joon Byun, Chuang-Ming Zheng, Sungmin Moon, Soo Jeong Jo, Ho Won Kang, Won Tae Kim, Yung Hyun Choi, Sung-Kwon Moon, Wun-Jae Kim, Xuan-Mei Piao, and Seok Joong Yun
- Subjects
NON-muscle invasive bladder cancer ,BLADDER cancer ,BIOMARKERS ,PROGRESSION-free survival ,POLYMERASE chain reaction ,LOG-rank test - Abstract
Purpose: T1 high grade (T1HG) bladder cancer (BC) is a type of non-muscle invasive BC (NMIBC) that is recognized as an aggressive subtype with a heightened propensity for progression. Current risk stratification methods for NMIBC rely on clinicopathological indicators; however, these approaches do not adequately capture the aggressive nature of T1HG BC. Thus, new, more accurate biomarkers for T1HG risk stratification are needed. Here, we enrolled three different patient cohorts and investigated expression of collagen type VI alpha 1 (COL6A1), a key component of the extracellular matrix, at different stages and grades of BC, with a specific focus on T1HG BC. Materials and Methods: Samples from 298 BC patients were subjected to RNA sequencing and real-time polymerase chain reaction. Results: We found that T1HG BC and muscle invasive BC (MIBC) exhibited comparable expression of COL6A1, which was significantly higher than that by other NMIBC subtypes. In particular, T1HG patients who later progressed to MIBC had considerably higher expression of COL6A1 than Ta, T1 low grade patients, and patients that did not progress, highlighting the aggressive nature and higher risk of progression associated with T1HG BC. Moreover, Cox and Kaplan–Meier survival analyses revealed a significant association between elevated expression of COL6A1 and poor progression-free survival of T1HG BC patients (multivariate Cox hazard ratio, 16.812; 95% confidence interval, 3.283–86.095; p=0.001 and p=0.0002 [log-rank test]). Conclusions: These findings suggest that COL6A1 may be a promising biomarker for risk stratification of T1HG BC, offering valuable insight into disease prognosis and guidance of personalized treatment decisions. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Role of Neoadjuvant Chemotherapy on Pathological, Functional, and Survival Outcomes of Upper Tract Urothelial Carcinoma Patients: A Systematic Review and Meta-Analysis.
- Author
-
Deb, Abdalla Ali, Chitteti, Pragnitha, Naushad, Naufal, Asaad, Wael, Leung, Steve, Hartley, Alice, and Serag, Hosam
- Subjects
ADJUVANT chemotherapy ,EVALUATION of medical care ,RESEARCH ,META-analysis ,CONFIDENCE intervals ,SYSTEMATIC reviews ,CANCER patients ,TRANSITIONAL cell carcinoma ,TUMOR classification ,DESCRIPTIVE statistics ,COMBINED modality therapy ,PROGRESSION-free survival ,INFORMATION storage & retrieval systems ,DATA analysis software - Abstract
The role of neoadjuvant chemotherapy (NAC) in upper tract urothelial cancer (UTUC) is not yet confirmed. Therefore, we conducted this review to pool the available evidence in this regard. We analyzed 14 117 UTUC patients reported in 21 studies after searching 5 databases. The NAC was administered in 1983 patients and the remaining 12 134 controls underwent radical nephroureterectomy (RNU) alone. Efficacy endpoints included pathological, functional, and survival outcomes. Safety was determined by overall and grade 3-4 complications. For dichotomous outcomes, the log odds ratio (logOR) was pooled, and for continuous variables, the crude mean difference was calculated along with its 95% CI. The NAC was associated with 10% complete pathological response (CPR), 42% pathological downstaging, 31% post-NAC advanced disease (pT3-4), 6% positive surgical margin, 18% lymph node metastasis (pN+), 24% lymphovascular invasion, and 29% mortality and recurrence at 5 years. Compared to controls, NAC resulted in increased risk of CPR [logOR = 1.67; 95% CI, 0.11-3.23] and downstaging [logOR = 1.30; 95% CI, 0.41-2.18] and reduced risk of advanced disease [logOR = -0.81; 95% CI, -1.51--0.11]. Renal function did not improve from baseline; however, it increased significantly after RNU. The NAC was associated with good survival/low mortality in the short term, with a sustained increase over time. Overall and grade 3-4 complications occurred in 25% and 7% of patients, respectively. Our findings support the potential benefits of NAC in enhancing pathological outcomes and possibly improving survival in UTUC patients undergoing RNU. The variability in response and associated complications underscore the importance of careful patient selection and tailored treatment approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. A single-center retrospective comparison of pT1 substaging methods in bladder cancer.
- Author
-
Kläger J, Koeller MC, Oszwald A, Wasinger G, D'Andrea D, and Compérat E
- Abstract
Substaging of T1 urothelial cancer is associated with tumor progression and its reporting is recommended by international guidelines. However, it has not been integrated in risk stratification tools and there is no agreement on the best method to use for its reporting. We aimed to investigate the applicability, interobserver variability, and prognostic value of histological landmark based and micrometric (aggregate linear length of invasive carcinoma (ALLICA), microscopic vs. extensive system, Rete Oncologica Lombarda (ROL) system) substaging methods. A total of 79 patients with the primary diagnosis of T1 urothelial cancer treated with conventional transurethral resection and adjuvant BCG therapy between 2000 and 2020 at the Medical University of Vienna were included. The anatomical and metrical substaging systems were evaluated using agreement rate, Cohen's kappa, Kendall's tau, and Spearman rank correlation. Prognostic value for high-grade recurrence or T2 progression was evaluated in uni- and multivariable analysis. Applicability and reproducibility were good to moderate and varied between substaging methods. Obstacles are mainly due to fragmentation of samples. Anatomical substaging was associated with progression in univariable and multivariable analysis. In our cohort, we could only identify anatomical landmark-based substaging to be prognostic for T2 progression. A major obstacle for proper pathological assessment is fragmentation of samples due to operational procedure. Avoiding such fragmentation might improve reproducibility and significance of pathological T1 substaging of urothelial cancer., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
14. [Can muscle invasive bladder cancer be treated without cystectomy in the future? : New data on trimodal therapy and bladder preservation after systemic therapy alone].
- Author
-
Hausmann J and Grunewald CM
- Abstract
Muscle invasive bladder cancer is generally an aggressive disease. Radical cystectomy (RC) is traditionally the treatment of choice. Due to possible advantages in morbidity, peri-interventional mortality, and quality of life, bladder-preserving treatment strategies are of interest. Here, trimodal therapy (TMT) consisting of maximum transurethral resection and subsequent radiochemotherapy with subsequent cystoscopic follow-up plays an important role. Current cohort analyses indicate equivalent oncological results of TMT to RC in selected patients. However, the use of systemic therapy alone with combined chemo-/immunotherapy or cytotoxic combination therapy also shows promising efficacy both in early surrogate parameters and in oncological endpoints. Overall, studies to date suggest that bladder preservation is possible without compromising oncologic outcomes. Future developments aim to refine patient selection by combining different risk factors and biomarkers to further improve outcomes., (© 2024. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
15. Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.
- Author
-
Li R, Shah PH, Stewart TF, Nam JK, Bivalacqua TJ, Lamm DL, Uchio EM, Geynisman DM, Jacob JM, Meeks JJ, Dickstein R, Pearce SM, Kang SH, Jung SI, Kamat AM, Burke JM, Keegan KA, and Steinberg GD
- Subjects
- Humans, Female, Male, Aged, Middle Aged, Combined Modality Therapy, Aged, 80 and over, Oncolytic Viruses genetics, Antineoplastic Agents, Immunological therapeutic use, Carcinoma in Situ therapy, Carcinoma in Situ pathology, Carcinoma in Situ drug therapy, Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms therapy, Urinary Bladder Neoplasms pathology, Urinary Bladder Neoplasms drug therapy, Antibodies, Monoclonal, Humanized therapeutic use, Oncolytic Virotherapy methods, BCG Vaccine therapeutic use, BCG Vaccine administration & dosage, BCG Vaccine adverse effects, Adenoviridae genetics
- Abstract
Cretostimogene grenadenorepvec is a serotype-5 oncolytic adenovirus designed to selectively replicate in cancer cells with retinoblastoma pathway alterations, previously tested as monotherapy in bacillus Calmette-Guérin (BCG)-experienced non-muscle-invasive bladder cancer. In this phase 2 study, we assessed the potential synergistic efficacy between intravesical cretostimogene and systemic pembrolizumab in patients with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ (CIS). Thirty-five patients were treated with intravesical cretostimogene with systemic pembrolizumab. Induction cretostimogene was administered weekly for 6 weeks followed by three weekly maintenance infusions at months 3, 6, 9, 12 and 18 in patients maintaining complete response (CR). Patients with persistent CIS/high-grade Ta at the 3-month assessment were eligible for re-induction. Pembrolizumab was administered for up to 24 months. The primary endpoint was CR at 12 months as assessed by cystoscopy, urine cytology, cross-sectional imaging and mandatory bladder mapping biopsies. Secondary endpoints included CR at any time, duration of response, progression-free survival and safety. The CR rate in the intention-to-treat population at 12 months was 57.1% (20 out of 35, 95% confidence interval (CI) 40.7-73.5%), meeting the primary endpoint. A total of 29 out of 35 patients (82.9%, 95% CI 70.4-95.3%) derived a CR at 3 months. With a median follow-up of 26.5 months, the median duration of response has not been reached (95% CI 15.7 to not reached). The CR rate at 24 months was 51.4% (18 out of 35) (95% CI 34.9-68.0%). No patient progressed to muscle-invasive bladder cancer in this trial. Adverse events attributed to cretostimogene were low grade, self-limiting and predominantly limited to bladder-related symptoms. A total of 5 out of 35 patients (14.3%) developed grade 3 treatment-related adverse effects. There was no evidence of overlapping or synergistic toxicities. Combination intravesical cretostimogene and systemic pembrolizumab demonstrated enduring efficacy. With a toxicity profile similar to its monotherapy components, this combination may shift the benefit-to-risk ratio for patients with BCG-unresponsive CIS. ClinicalTrials.gov Identifier: NCT04387461 ., (© 2024. The Author(s), under exclusive licence to Springer Nature America, Inc.)
- Published
- 2024
- Full Text
- View/download PDF
16. Prognostic value of micrometric substaging in pT1 bladder cancer patients treated with en-bloc transurethral resection.
- Author
-
Yanagisawa T, Sato S, Hayashida Y, Okada Y, Matsukawa A, Iwatani K, Shimoda M, Takahashi H, Kimura T, Shariat SF, and Miki J
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Retrospective Studies, Prognosis, Aged, 80 and over, Neoplasm Recurrence, Local pathology, Cystectomy methods, Adult, Neoplasm Staging, Neoplasm Invasiveness, Disease Progression, Disease-Free Survival, Urinary Bladder Neoplasms pathology, Urinary Bladder Neoplasms surgery, Urinary Bladder Neoplasms mortality
- Abstract
Aims: We aimed to assess the oncological impact of micrometric extent of invasion in patients with pT1 bladder cancer (BCa) who underwent en-bloc resection for bladder tumour (ERBT)., Methods and Results: We retrospectively analysed the records and specimens of 106 pT1 high-grade BCa patients who underwent ERBT. The extent of invasion, such as depth from basal membrane, number of invasive foci, maximum width of invasive focus, muscularis mucosae invasion and infiltration pattern (pattern A: solid sheet-like, nodular or nested growth, pattern B: trabecular, small cluster or single-cell pattern) were evaluated by a single genitourinary pathologist. The end-points were recurrence-free (RFS) and progression-free survival (PFS). Within a median follow-up of 23 months, overall, 36 patients experienced recurrence and 13 patients experienced disease progression. The 2-year PFS differed significantly depending on depth from basal membrane (< 1.3 mm: 94.8% versus ≧ 1.3 mm: 65.2%, P = 0.005), maximum width of invasive focus (< 4 mm: 91.7% versus ≧ 4 mm: 62.3%, P < 0.001), muscularis mucosae (MM) invasion (above MM = 96.1% versus into or beyond MM = 64.8%, P = 0.002) and infiltration pattern (pattern A: 100% versus pattern B: 83.3%, P = 0.037). In a multivariable analysis, MM invasion [hazard ratio (HR) = 4.54, 95% confidence interval (CI) = 1.25-16.5] and maximum width of invasive focus ≧ 4 mm (HR = 4.79, 95% CI = 1.25-16.5) were independent prognostic factors of progression., Conclusions: En-bloc resection facilitates the evaluation of pathologic variables that might be useful in predicting disease recurrence and progression. In particular, not only the MM invasion but also the maximum width of invasion focus, reflecting the invasive volume, appear to be reliable prognosticators for disease progression., (© 2024 The Authors. Histopathology published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
17. Influence of lamina propria invasion extension on T1 high-grade non-muscle-invasive bladder cancer in patients undergoing BCG or radical cystectomy.
- Author
-
Contieri R, Tan WS, Grajales V, Hensley PJ, Martini A, Bree K, Myers A, Nogueras-Gonzalez G, Navai N, Dinney CP, Guo C, and Kamat AM
- Subjects
- Aged, Female, Humans, Male, Middle Aged, Adjuvants, Immunologic therapeutic use, Neoplasm Grading, Neoplasm Staging, Prognosis, Retrospective Studies, BCG Vaccine therapeutic use, Cystectomy, Mucous Membrane pathology, Neoplasm Invasiveness, Non-Muscle Invasive Bladder Neoplasms mortality, Non-Muscle Invasive Bladder Neoplasms surgery
- Abstract
Objective: To evaluate the prognostic value of T1 substaging in patients treated with bacillus Calmette-Guérin (BCG) or immediate radical cystectomy (iRC)., Materials and Methods: We performed an institutional review board-approved retrospective study analysing non-muscle-invasive bladder cancer (NMIBC) patients with pT1 disease treated with either BCG or iRC between 2000 and 2020. Lamina propria (LP) invasion characteristics were extracted from the pathology report. The Kaplan-Meier method was used to calculate overall survival (OS), cancer-specific survival (CSS) and metastasis-free survival (MFS). Multivariable Cox models were used to determine the association between progression-free survival (PFS) and characteristics in the BCG cohort. A logistic regression model explored the relationship between T1 substaging and upstaging to >pT2 at iRC., Results: A total of 411 T1 high-grade patients were identified. LP invasion characteristics were as follows: not specified: 115 (28%); focal/superficial (F/S): 147 (35.8%); and extensive/multifocal (E/M): 149 (36.2%). Overall, 303 patients (73.7%) received BCG, and 108 patients (26.3%) underwent iRC. The median (interquartile range) follow-up was 53 (32-96) months. Patients with E/M LP invasion were significantly more likely to undergo iRC (34% vs. 19%; P = 0.003). Patients with E/M LP invasion showed poorer MFS and CSS compared to those with F/S LP invasion when treated with BCG but not when treated with iRC. Among BCG-treated patients, progression occurred in 41 patients and E/M LP invasion was independently associated with progression after BCG (hazard ratio 5.3, 95% confidence interval [CI] 2.2-13.1; P < 0.001). T1 substaging was not associated with upstaging at RC (odds ratio 3.15, 95% CI 0.82-12.12; P = 0.095)., Conclusions: Extensive/multifocal LP invasion was associated with poor PFS, MFS and CSS in patients treated with BCG. T1 substaging provides valuable prognostic information and should be reported in pathology reports., (© 2024 BJU International.)
- Published
- 2024
- Full Text
- View/download PDF
18. Peimenine unleashes therapeutic promise in urothelial bladder cancer: inhibition of proliferation, induction of cell death and modulation of key pathways.
- Author
-
Yang Z, Guo R, Bi Y, Xu W, Hao M, Liang Y, Li Y, Wang H, Zhang J, Xie J, Wan C, and Sun J
- Subjects
- Humans, Cell Line, Tumor, Animals, Mice, Apoptosis drug effects, Mice, Nude, Antineoplastic Agents pharmacology, Antineoplastic Agents chemistry, Mice, Inbred BALB C, Xenograft Model Antitumor Assays, Cell Movement drug effects, Signal Transduction drug effects, Urinary Bladder Neoplasms drug therapy, Urinary Bladder Neoplasms pathology, Urinary Bladder Neoplasms metabolism, Cell Proliferation drug effects
- Abstract
Peimenine (PEI) is a steroid alkaloid substance isolated from Fritillaria thunbergii bulbs. It has various pharmacological activities, such as relief from coughs and asthma, expectorant properties, antibacterial effects, sedative qualities, and anti-inflammatory properties. Notably, PEI can effectively inhibit the proliferation and tumor formation of liver cancer and osteosarcoma cells by inducing autophagic cell death. However, the precise effect and mechanisms of PEI on urothelial bladder cancer (UBC) cells remain uncertain. Thus, this study aims to investigate the impact of PEI on UBC cells both in vivo and in vitro. The IC
50 values of BIU-87 and EJ-1 cells after 48 h were 710.3 and 651.1 μg/mL, respectively. Additionally, PEI blocked the cell cycle in BIU-87 and EJ-1 cells during the G1 phase. Furthermore, it hindered the migration of BIU-87 and EJ-1 cells substantially. PEI significantly inhibited the tumor development of EJ-1 cells within the xenograft tumor model in vivo. Mechanically, PEI augmented the protein and mRNA expression of BIM, BAK1, and Cytochrome C (CYCS) in UBC cells. Taken together, PEI suppressed the proliferation of UBC cells both in vitro and in vivo by inducing cell death and cell cycle arrest, suggesting that PEI could be applied in the treatment of UBC., (© 2024 John Wiley & Sons Ltd.)- Published
- 2024
- Full Text
- View/download PDF
19. Adding a Gene Expression Profile Test to Aid Differential Diagnosis and Treatment in Aggressive Large B-Cell Lymphoma: An Early Exploratory Economic Evaluation.
- Author
-
Bouttell J, Fraser H, Goodlad JR, Hopkins D, McKay P, Oien KA, Seligmann B, von Delft S, and Hawkins N
- Subjects
- Humans, Cost-Benefit Analysis, Bortezomib therapeutic use, Diagnosis, Differential, Doxorubicin therapeutic use, Rituximab therapeutic use, Cyclophosphamide therapeutic use, Quality-Adjusted Life Years, Transcriptome, Lymphoma, Large B-Cell, Diffuse diagnosis, Lymphoma, Large B-Cell, Diffuse drug therapy, Lymphoma, Large B-Cell, Diffuse genetics
- Abstract
Background and Objective: Adding gene expression profiles (GEPs) to the current diagnostic work-up of aggressive large B-cell lymphomas may lead to the reclassification of patients, treatment changes and improved outcomes. A GEP test is in development using TempO-Seq
® technology to distinguish Burkitt lymphoma (BL) and primary mediastinal large B-cell lymphoma (PMBCL) from diffuse large B-cell lymphoma (DLBCL), and to classify patients with DLBLC and to predict the benefit of (e.g.) adding bortezomib to R-CHOP therapy (RB-CHOP). This study aims to estimate the potential impact of a GEP test on costs and health outcomes to inform pricing and evidence generation strategies., Methods: Three decision models were developed comparing diagnostic strategies with and without GEP signatures over a lifetime horizon using a UK health and social care perspective. Inputs were taken from a recent clinical trial, literature and expert opinion. We estimated the maximum price of the test using a threshold of Great Britain Pound (GBP) 30,000 per quality-adjusted life-year (QALY). Sensitivity analyses were conducted., Results: The estimated maximum threshold price for a combined test to be cost effective is GBP 15,352. At base-case values, the BL signature delivers QALY gains of 0.054 at an additional cost of GBP 275. This results in a net monetary benefit at a threshold of GBP 30,000 per QALY of GBP 1345. For PMBCL, the QALY gain was 0.0011 at a cost saving of GBP 406 and the net monetary benefit was GBP 437. The hazard ratio for the impact of treating BL less intensively must be at least 1.2 for a positive net monetary benefit. For identifying patients with the DLBCL subtype responsive to bortezomib, QALY gain was 0.2465 at a cost saving of GBP 6175, resulting in a net monetary benefit of GBP 13,570. In a probabilistic sensitivity analysis using 1000 simulations, a testing strategy was superior to a treat all with R-CHOP strategy in 81% of the simulations and with a cost saving in 92% assuming a cost price of zero., Conclusions: Our estimates show that the combined test has a high probability of being cost effective. There is good quality evidence for the benefit of subtyping DLBCL but the evidence on the number of patients reclassified to or from BL and PMBCL and the impact of a more precise diagnosis and the cost of treatment is weak. The developers can use the price estimate to inform a return on investment calculations. Evidence will be required of how well the TempO-Seq® technology performs compared to the testing GEP technology used for subtyping in the recent clinical trial. For BL and PMBCL elements of the test, evidence would be required of the number of patients reclassified and improved costing information would be useful. The diagnostic and therapeutic environment in haematological malignancies is fast moving, which increases the risk for developers of diagnostic tests., (© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)- Published
- 2024
- Full Text
- View/download PDF
20. pT1 Subclassification Predicts Progression-Free Survival in En Bloc Resection of Bladder Tumor Specimens
- Author
-
Sato, Shun, Yanagisawa, Takafumi, Miki, Jun, Hayashida, Yasushi, Okada, Yohei, Iwatani, Kosuke, Matsukawa, Akihiro, Kimura, Takahiro, Egawa, Shin, Shimoda, Masayuki, and Takahashi, Hiroyuki
- Subjects
Tumors -- Prognosis -- Development and progression ,Cancer patients -- Prognosis ,Bladder cancer -- Prognosis -- Development and progression ,Surgery -- Analysis ,Health - Abstract
* Context.--The pathologic diagnosis of pT1 substage in conventional transurethral resection of bladder tumor specimens is inaccurate and has low interobserver reproducibility owing to fragmentation and cauterization of the specimens. En bloc resection of bladder tumor is a novel surgical procedure that improves diagnostic feasibility and accuracy in the pathologic diagnosis of bladder cancer, including depth and extent of invasion. Objective.--To examine the prognostic value of multiple pT1 subclassification methods, using only en bloc resection specimens. Design.--We examined 106 patients with T1 bladder cancer who underwent en bloc resection. The pT1 substages were assigned by 3 different subclassification methods by using the muscularis mucosae or stalk of the papillary lesion as diagnostic landmarks or millimetric depth of invasion. Intergroup differences in progression-free survival and recurrence-free survival rates were analyzed. The prognostic values of clinicopathologic factors for progression/recurrence were analyzed by using multivariate analysis. Results.--The pT1 substage was evaluable in all cases. Tumors with invasion into/beyond the muscularis mucosae and those beyond the stalk of the papillary lesion were associated with worse progression-free survival (P = .002 and P = .01, respectively). Notably, no patient with invasion confined to the stalk had disease progression during the 23-month median follow-up period. Only the pT1 subclassification method using the muscularis mucosae was an independent prognosticator of progression in multivariate analysis (P = .03). Conclusions.--Precise pathologic subclassification of invasion using en bloc resection specimens may enable accurate prognosis and assessment in patients with bladder cancer with suspicious shallow invasion., Non-muscle-invasive bladder cancer (BCa), including T1 cancer, comprises 70% to 80% of untreated BCas. Among the non-muscle-invasive BCas, T1 BCa comprises a relatively large proportion, from 20% to 25%. (1-3) [...]
- Published
- 2024
- Full Text
- View/download PDF
21. Kann beim muskelinvasiven Urothelkarzinom der Harnblase zukünftig auf die Zystektomie verzichtet werden?: Neue Daten zur trimodalen Therapie und zum Blasenerhalt nach reiner Systemtherapie
- Author
-
Hausmann, Jan and Grunewald, Camilla M.
- Published
- 2024
- Full Text
- View/download PDF
22. Tata Memorial Centre Textbook of Oncology
- Author
-
Rajendra A. Badwe, Sudeep Gupta, Shailesh V. Shrikhande, Siddhartha Laskar, Rajendra A. Badwe, Sudeep Gupta, Shailesh V. Shrikhande, and Siddhartha Laskar
- Subjects
- Internal medicine, Surgery, Radiology
- Abstract
The Tata Memorial Centre Textbook of Oncology is an authoritative and comprehensive book, meticulously compiled to cover contemporary issues in oncology. It features contributions from 189 authors, culminating in 76 chapters. Authored by faculty members from the renowned Tata Memorial Centre, this textbook offers a harmonious blend of detailed information and practical approaches. It serves as a comprehensive resource that contextualizes the practice of oncology in TMC and offers insights into delivering high-quality cancer care in diverse settings. It offers an authentic overview of the TMC approach to multidisciplinary cancer care. The Textbook is designed to cater to a wide array of readers – from undergraduate medical students to postgraduates specializing in general surgery, general medicine, pediatrics, gynecology, radiation oncology, and other disciplines, and practicing community oncologists. A notable feature of the Textbook is its utility in preparing students for entrance and exit examinations. This book is an essential resource for established cancer specialists, including surgeons, medical oncologists, radiation oncologists, and those in allied fields. It is also invaluable for super-specialty students and postgraduates with an interest in cancer management, offering a comprehensive guide to the dynamic field of oncology.
- Published
- 2024
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.